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A B S T R A C T
The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness) Chikungunya (CHIKV),
O'nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group is investigating the natural history, epide-
miology and medical management of infection by these viruses, to identify knowledge gaps and to propose
recommendations for direct future investigations and rectification measures. Here, we present the first report
dedicated to diagnostic aspects of CHIKV, ONNV and MAYV. Regarding diagnosis of the disease at the acute
phase, molecular assays previously described for the three viruses require further evaluation, standardized
protocols and the availability of international standards representing the genetic diversity of the viruses.
Detection of specific IgM would benefit from further investigations to clarify the extent of cross-reactivity among
the three viruses, the sensitivity of the assays, and the possible interfering role of cryoglobulinaemia.
Implementation of reference panels and external quality assessments for both molecular and serological assays is
necessary. Regarding sero-epidemiological studies, there is no reported high-throughput assay that can distin-
guish among these different viruses in areas of potential co-circulation. New specific tools and/or improved
standardized protocols are needed to enable large-scale epidemiological studies of public health relevance to be
performed. Considering the high risk of future CHIKV, MAYV and ONNV outbreaks, the Working Group re-
commends that a major investigation should be initiated to fill the existing diagnostic gaps.
1. Introduction
The GloPID-R (Global Research Collaboration for Infectious Disease
Preparedness) Chikungunya (CHIKV), O'nyong-nyong (ONNV) and
Mayaro virus (MAYV) Working Group presents a report dedicated to
diagnostic aspects of these pathogens. Overlapping clinical presenta-
tions, wide geographic spread and the possible selection of viruses
capable of transmission by new vectors highlight the need for labora-
tory diagnostic support to unambiguously identify etiological agents in
cases of undefined febrile illness with arthralgia and/or rash. This is
important to ensure an early detection of cases and to support a clinical
and public health response.
In order to assess the currently available molecular and serological
tools to diagnose infections by CHIKV, ONNV and MAYV, the experts of
the GloPID-R have performed a systematic review of English literature
on the diagnostic aspects of the three viruses present on PubMed until
September 2018. Diagnosis of the diseases at the acute phase mostly
relies on molecular detection of the virus genomes: we discussed about
kinetics of viral loads and biological sampling, choice of molecular tool,
available in-house and commercial molecular tests, international stan-
dards and external quality assessments organized to investigate la-
boratories’ capability for viral detection. Alternatively, diagnosis can be
provided by the detection of specific antibodies, so we focused on ki-
netics of immune response, choice of serological tool, commercially
available tests, international standards and external quality assess-
ments; moreover, cryoglobulinaemia and cross-reactivity, that can in-
terfere with the correct identification of antibodies, were discussed, as
well as cross-protection and cross-neutralization among the three pa-
thogens.
Viral isolation by culture has not been taken into account because
its turnaround time hardly fits with the need for an early diagnosis.
Although in some cases (i.e. 2005–2006 CHIKV outbreak in Mauritius
Pyndiah et al. (2012)) virus isolation has been performed for laboratory
diagnosis with good sensitivity, providing results 2–3 days after in-
oculation, this diagnostic modality is being replaced by molecular
techniques including RT-PCR, that are faster, more sensitive and safer
and require less laboratory infrastructure. However, virus isolation re-
mains a crucial tool in reference laboratories to characterize circulating
strains to support control and development of diagnostic tools.
In this report, the experts identified knowledge gaps and provided
adapted recommendations. The objective was to suggest relevant re-
search priorities in the field, in order to improve individual patient care
and outbreak management.
2. Background
2.1. Epidemiology
At least 5 million cases over the last 15 years (Chikungunya, 2018)
are reason enough to recognize Chikungunya virus (CHIKV) as an
emerging global health threat. Data from the two largest CHIKV epi-
demics so far highlight the ability of the virus to spread rapidly over
great distances and in multiple locations. During the 2004–2006 out-
break in the Indian Ocean region, attack rates peaked at 63% in the
Comoro Islands; La Réunion Island registered 47,000 cases in a single
week (January 30th to February 5th, 2006), with almost 40% of the
population estimated to have experienced CHIKV disease; India re-
corded at least 1.4 million cases at the end of 2006. In late 2013, CHIKV
emerged in the New World, when in the island of Saint Martin CHIKV
infection was identified in patients with no history of travel abroad. The
virus spread to 45 countries and territories in North, Central, and South
America and the Caribbean Islands; by the end of 2017, 544 deaths
directly or indirectly related to the outbreak in the Americas were re-
corded, together with 2.5 million cases of infections. Transmission is
ongoing in some locations (PAHO WHO, 2019).
CHIKV is a mosquito-transmitted alphavirus belonging to the family
Togaviridae (Powers and Logue, 2007). The two major vectors of the
disease are Aedes (Stegomyia) aegypti and Ae. (Steg.) albopictus (Vega-
Rua et al., 2014), the latter identified during the 2004–2006 outbreak
in the Indian Ocean, when the first in a series of adaptive mutations in
the glycoprotein genes of the virus increased its replication in this
specific vector (Schuffenecker et al., 2006; Tsetsarkin et al., 2016). Two
transmission cycles have been described. A sylvatic cycle maintains
CHIKV in Africa involving forest-dwelling mosquito species (such as Ae.
africanus and Ae. furcifer–taylori) and mainly nonhuman primates
(Althouse et al., 2018); in this context, humans are incidental hosts and
become infected when they enter the forest or when infected vectors
invade adjacent villages from the forest. Several wild animal species,
especially nonhuman primates, have been investigated as possible virus
reservoirs sustaining virus circulation in the environment in the ab-
sence of human cases (Diallo et al., 1999). CHIKV can also be main-
tained through an urban human-mosquito-human transmission cycle,
that involves Ae. aegypti and Ae. Albopictus mosquitoes; this cycle has
been observed in the Americas, Indian Ocean, Asia and, more recently,
Europe. In this urban context, humans can serve as reservoir and am-
plification hosts (Thiberville et al., 2013a).
Several factors contribute to massive CHIKV circulation: e.g. high
mosquito densities, including following recent invasions of the main
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urban vectors, Aedes species; vectorial capacity in transmitting the virus
(high susceptibility to CHIKV as well as preference for feeding on
human beings); high viremia level in infected humans; large population
of susceptible individuals exposed for the first time in several countries;
increasing travel from countries with ongoing circulation that enables
importation of viremic cases into virus-naïve regions, allowing the virus
to extend its geographic distribution if conditions for local transmission
are present.
CHIKV forms, with seven other alphaviruses, the Semliki Forest
serocomplex, in which E1 envelope glycoprotein gene amino acid se-
quence divergence is below 40% (Powers et al., 2001). Among this
serocomplex, viruses from the species Mayaro virus (MAYV) and
O'nyong-nyong virus (ONNV) are of particular interest because they have
potential to emerge in the human population (Hotez and Murray, 2017;
Lwande et al., 2015).
ONNV is transmitted by anopheline mosquitoes; it is probably
maintained through an enzootic cycle that has not been characterized
yet, and humans can serve as amplification hosts during epidemics
(Rezza et al., 2017). MAYV is transmitted by Haemagogus species
mosquitoes in an enzootic cycle in which nonhuman primates seem to
be the main amplifier vertebrate hosts, with limited spillover to humans
who frequently enter forest habitats (Mackay and Arden, 2016).
CHIKV, ONNV and MAYV are phylogenetically related: they share
some features that make differential diagnosis among the three viruses
a challenging task.
2.2. Clinical presentation
Infections by CHIKV, ONNV and MAYV share an apparent similar
clinical picture, with a “dengue-like” syndrome (Thiberville et al.,
2013a; Rezza et al., 2017; Mackay and Arden, 2016). This typically
includes fever, headache and a papular or maculopapular rash during
the acute stage, together with a more specifically remarkable in-
capacitating polyarthralgia, which is the hallmark of these so-called
“alphavirus arthritogenic diseases”. Although disease is generally self-
limiting, severe joint pain can persist for months or even years in some
individuals (Heath et al., 2018).
2.3. Co-circulation
CHIKV impacts human health globally, with local transmission re-
ported in Asia, Africa, Europa, Americas, Pacific region and, transiently,
in Europe (Thiberville et al., 2013a; Lwande et al., 2015). MAYV cir-
culation has mostly been limited to South America with sporadic out-
breaks next to forest environments (Schmidt et al., 1959; Anderson
et al., 1957; LeDuc et al., 1981). Recently detected MAYV infections in
Haiti in a patient with no history of travel abroad living in a non-forest
area, and in Panama suggest (I) the spread of the virus towards Central
America and the Caribbean and (II) a possible human-to-human
transmission (Lednicky et al., 2016; Carrera et al., 2018). ONNV is
endemic in sub-Saharan Africa and it has been associated with sporadic
large-scale epidemics. The first one, in 1959–1962, accounted for more
than 2 million cases in eastern Africa alone (Haddow et al., 1960); then,
after an apparent absence of about 35 years, ONNV re-emerged in
Uganda in 1996 (Rwaguma et al., 1997), showing again its potential to
cause massive outbreaks. Moreover, the actual distribution of ONNV in
Africa is likely to be broader. Limited availability of diagnostic tools
may have led to confusion of ONNV and CHIKV outbreaks (LaBeaud
et al., 2015).
Co-circulation of CHIKV-MAYV in Southern and Central America
and CHIKV-ONNV in the African continent, do not allow to make a
reliable diagnosis based on the geographic area where the infection is
contracted; moreover, the wide circulation of other pathogens causing
febrile illness (such as dengue virus and malaria-causing Plasmodium
species) makes a travel history of the patient insufficient to narrow the
differential diagnosis (Cleton et al., 2012).
2.4. Transmission vectors
The three viruses do not share the same main mosquito vectors:
CHIKV is primarily transmitted by Aedes spp; ONNV is unique among
alphaviruses in its adaptation to Anopheles spp; MAYV enzootic vectors
are mostly Haemagogus spp (Coffey et al., 2014; Williams et al., 1965;
Hoch et al., 1981). However, experimental evidence that Aedes mos-
quitoes can transmit ONNV and MAYV exists (Vanlandingham et al.,
2005; Long et al., 2011; Smith and Francy, 1991), with a productive
viral replication both in vitro and in vivo. As CHIKV has taught us, a
single amino-acid change in the virus can result in increased vector
competence from a mosquito species not normally considered a primary
vector (Tsetsarkin et al., 2007). The adaptation of CHIKV leading to
higher competence of Ae. albopictus for virus transmission among hu-
mans illustrates that virus evolution might drive the involvement of
other, more anthropophilic mosquito species.
3. Chikungunya virus (CHIKV)
3.1. Molecular diagnosis
3.1.1. Kinetics of viral load and dedicated biological sampling
CHIKV infections are characterized by high viremia levels (range:
104-108 RNA copies/mL (Laurent et al., 2007; Lanciotti et al., 2006))
during the acute phase, which includes the first 3–4 days after illness
onset (Chow et al., 2011; Thiberville et al., 2013b). This stage is fol-
lowed by a rapid decrease of viremia (Chusri et al., 2014): in 2008,
Panning et al. (2008) showed that real-time RT-PCR was 100% positive
for all sera collected up to day 4 after illness onset, with sensitivity
subsequently decreasing to 40% at day 7. Similarly, CHIKV loads have
been proved to decrease significantly in serum from 5 days after the
onset of symptoms onwards (Bozza et al., 2019). Even if some persisting
cases of viremia have been observed (up to 17 days) (Win et al., 2010;
Appassakij et al., 2013; Leo et al., 2009), molecular diagnosis should
typically be performed within the first 7 days on an acute-phase spe-
cimen to confirm CHIKV infection (Appassakij et al., 2013; Reddy et al.,
2012; Musso et al., 2016).
The preferred samples for diagnosis are serum or plasma (Lanciotti
et al., 2006; Panning et al., 2008; Appassakij et al., 2013; Musso et al.,
2016; Diagnostic Testing, 2017), but other clinical samples have been
evaluated for use in diagnosis.
3.1.1.1. Saliva. Saliva showed a lower sensitivity compared to blood
for CHIKV: it has been observed that for confirmed CHIKV cases (by
IgM or PCR in blood (WER9033_410-414)) presenting during the 1st
week after illness onset, detection rate in saliva was 58,3% compared to
86,1% in blood samples (Musso et al., 2016). Accordingly, testing saliva
can be relevant during the 1st week post-symptoms onset if blood
samples are difficult or impossible to collect, but is associated with
decreased detection rate and lower negative predictive value.
3.1.1.2. Semen. Interestingly, semen has been found positive for a
prolonged period of time after symptom onset (30 days), providing
an expanded window for the molecular diagnosis of a recent infection
with CHIKV (Bandeira et al., 2016). This finding needs to be further
investigated, in order to assess the risk of sexual transmission of CHIKV
and how this risk compares to the recently observed sexual transmission
of other mosquito-borne viruses such as Zika virus (Mead et al., 2018).
3.1.1.3. Urine. The same study showed CHIKV RNA 30 days after
initial symptoms in urine from a patient with a positive semen
sample (Bandeira et al., 2016). Similarly, viral genomes were present
up to day 30 post-infection in the urine of infected mice, long after viral
clearance from the plasma (Jones and Okeoma, 2015). Recently, a case
report described a patient with meningoencephalitis and ocular lesions
having a positive urine sample 40 days after illness onset (Rocha et al.,
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2018). However, Musso et al. (2016) did not observe a prolonged
window of detection of CHIKV in urine, with samples testing positive by
PCR only if collected during the first week after symptoms onset. For
confirmed CHIKV patients presenting during the first 7 days after illness
onset, the detection rate in the urine was 8.3% compared to 86.1% in
blood; after the 1st week after symptom onset, it decreased to 0%, with
no positive urine samples that could confirm serological diagnosis of
CHIKV infection (IgM+). Bozza et al. observed low viral loads in the
urine of patients with confirmed CHIKV infection (Bozza et al., 2019).
Considering the contradictory results, virus shedding kinetics in urine
deserve a systematic re-assessment with enough power in the cohort
size.
3.1.1.4. Breast milk. Recently, the presence of CHIKV RNA in breast
milk was reported 23 days after the inception of symptoms in one
patient (Campos et al., 2017); however, another study could not detect
viral RNA in maternal milk in 8 samples collected during viremia
(although plasma samples from the same patients were RT-PCR
positive) (Grivard et al., 2007).
3.1.1.5. Cerebrospinal fluid. In cases of CHIKV infections with
neurological involvement, cerebrospinal fluid (CSF) samples can be
tested with both serological and virological assays, with several studies
describing detection of viral RNA in CSF (Rocha et al., 2018; Grivard
et al., 2007; Gérardin et al., 2016; Lemant et al., 2008; Chandak et al.,
2009; Nagpal et al., 2017; Taraphdar et al., 2015). Case reports suggest
that genomes can persist in the CSF for 7–10 days after illness onset
(Taraphdar et al., 2015; Casolari et al., 2008), with viral loads in the
CSF generally lower than in plasma (Grivard et al., 2007).
3.1.1.6. Other fluids and tissues. The virus has been detected also in
amniotic fluid, brain and liver biopsies, neonatal gastric fluids and
placenta (Grivard et al., 2007). Windows of detection of CHIKV
genomes in different samples are presented in Fig. 1.
3.1.2. Choice of test
Several diagnostic methods are available for viral genome detection.
Molecular assays targeting nucleic acids are sensitive methods in the
early stages of infection, before the rise of antiviral IgM antibodies
(Lanciotti et al., 2006). Isothermal amplification methods have been
described for CHIKV, i.e. loop-mediated isothermal amplification
(LAMP) and transcription-mediated amplification (TMA) (Lu et al.,
2012; Parida et al., 2007; Chiu et al., 2015). However, real-time RT-
PCR remains the most frequently used technique for routine diagnosis
at the acute stage of infection, because of its sensitivity, specificity and
ease of performance (Reddy et al., 2012). A positive result by real-time
RT-PCR is enough to make a reliable diagnosis of CHIKV, ONNV or
MAYV in areas where virus circulation has been previously docu-
mented. However, in case the virus is detected for the first time in a new
geographic area, it is good practice to confirm a positive result by RT-
PCR with a different test, to rule out a false-positive result caused by
laboratory contamination. Conventional RT-PCR is still employed for
research purposes (i.e. to identify to which lineage a viral strain belongs
(Lednicky et al., 2016; Bessaud et al., 2006; Calba et al., 2017)) but is
considered to be outdated for routine diagnostics.
3.1.3. In-house real-time RT-PCR
Several real-time RT-PCR systems have been published (Lanciotti
et al., 2006; Panning et al., 2008; Waggoner et al., 2016; Cecilia et al.,
2015; Smith et al., 2009; Edwards et al., 2007; Pastorino et al., 2005).
Some of them have been evaluated in the External Quality Assessment
(EQA) organized in 2014 by Jacobsen et al. (2016); their performances
are discussed in the paragraph 3.1.6. An alignment of 50 CHIKV se-
quences available in Genbank representing main lineages was made to
assess published in-house developed primer sets; GenBank accession
numbers and results of this in silico analysis are presented in Table 1.
Most PCR systems show one or more mismatches with CHIKV strains in
different proportion and positions; particular attention was given to
mismatches concerning the five 3’ terminal nucleotides of a primer,
because it is generally admitted that a single mutation in these positions
can significantly compromise detection capability of a primer. The table
highlights the fact that a number of available PCR systems are expected
to detect viruses from the WA lineage less efficiently than viruses from
the other lineages.
3.1.4. Commercial molecular tests
Several commercial tests from different companies were identified
for CHIKV molecular detection by real-time RT-PCR (Supplementary
data-Table 1). Some of them are formulated in monoplex format,
whereas others are multiplex assays targeting dengue virus (DENV) and
Zika virus (ZIKV) as well as in some cases yellow fever virus (YFV) and
usutu virus (USUV). RealStar from Altona Diagnostics (Hamburg, Ger-
many) is the only ready-to-use kit for real time RT-PCR evaluated in the
literature through the comparison with a published real-time RT-PCR
protocol (Panning et al., 2008, 2009a). The target region is within the
non-structural protein 1 (nsP1) gene and the manufacturer claims that
the kit allows detection of all three CHIKV genotypes; however, lack of
data on primers and probe sequences does not allow for an in silico
analysis to confirm this information, and only the ECSA genotype was
tested in the evaluation study. The 95% limit of detection (LOD) of the
kit is 3.2 genome copies per reaction using a quantified RNA from
CHIKV ECSA strain (RealStar, 2018). The evaluation study defined the
LOD using two different thermocyclers, Lightcycler 2.0 and Lightcycler
480. Using in vitro-transcribed RNA copies of a fragment of an ECSA
strain, 95% LOD was 5.3 copies per reaction with Lightcycler 2.0 and
3.8 copies per reaction with Lightcycler 480. Using a plaque-purified
and plaque-quantified CHIKV ECSA strain, LOD was 0.51 PFU/mL with
Lightcycler 2.0 and 0.34 PFU/mL with Lightcycler 480. High specificity
was established by the absence of cross-reactivity against a large panel
of non-CHIKV alphaviruses (including MAYV and ONNV) and non-al-
phaviruses. The RealStar assay had 100% sensitivity and specificity
when compared with the previously published real-time RT-PCR of
Panning et al. (2008), which has shown good sensitivity (95%) and
specificity (87,5%) values in the context of a multi-partner External
Quality Assessment (Jacobsen et al., 2016).
The RealStar kit has been used for testing blood donations prior to
transfusion as well as for CHIKV diagnosis in patients. The French Blood
Agency used it during the 2014 CHIKV Caribbean outbreak for
Fig. 1. Windows of detection of CHIKV genomes in different kinds of samples
by molecular methods. The letters in brackets indicate the references. (a):
(Lanciotti et al., 2006; Panning et al., 2008; Musso et al., 2016); (b): (Win et al.,
2010; Appassakij et al., 2013); (c): (Appassakij et al., 2013); (d): (Musso et al.,
2016); (e): (Bandeira et al., 2016; Jones and Okeoma, 2015); (f): (Rocha et al.,
2018); (g): (Musso et al., 2016); (h): (Bandeira et al., 2016); (i): (Casolari et al.,
2008); (j): (Taraphdar et al., 2015); (k): (Campos et al., 2017).
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individual NAT (nucleic acid testing) screening of blood products as a
part of implemented strategy to prevent CHIKV transfusion-transmitted
infections (TTIs) (Gallian et al., 2014).
According to the datasheet of the company, the FTD DENV/CHIKV
real time PCR kit from Fast-track Diagnostics has been evaluated with
EQA panels from Quality Control for Molecular Diagnostics (QCMD)
(Dengue Fever PCR Test, 2018); all samples (LeDuc et al., 1981) were
detected correctly except one.
During the 2014 CHIKV outbreak in the Americas, a prototype of
real-time CHIKV/DENV target-capture, transcription-mediated ampli-
fication (TC-TMA) assay by Hologic, Inc. (San Diego, CA, USA) was
used for high-throughput screening of blood products (Simmons et al.,
2016) on the Panther system (Hologic, Inc.). Tests were conducted
during and after the CHIKV epidemic in Puerto Rico in 2014 to detect
Asian genotype viruses in plasma samples. The Panther system auto-
mates all aspects of NAT-based blood screening on a single, integrated
platform; it is based on Procleix technology (developed by Hologic and
Grifols), already adapted for transfusion screening for HIV, HBV and
HCV. During the epidemic, high sensitivity was evidenced for both
individually tested samples and 16-sample minipools, with a 95% LOD
of 9.9 and 158 copies per reaction, respectively.
The same TC-TMA assay was used by another group in the same
period (2014 CHIKV Caribbean epidemic) (Chiu et al., 2015), with a
LOD of 8.2 copies/reaction. Positive TMA results were confirmed by
PCR, microarray and next-generation sequencing (NGS) analysis.
3.1.5. International standard (IS)
The first CHIKV RNA World Health Organization (WHO)
International Standard (IS) for Nucleic Acid Amplification Techniques
(NAAT)-Based Assays was accepted in October 2017 and is distributed
by the Paul Ehrlich Institute (Germany) (PEI, 2018). It has been pre-
pared from strain R91064 of the East/South/Central African (ECSA)
genotype (Indian Ocean lineage), isolated from a patient returning from
India to the USA in 2006 (Lanciotti et al., 2006). The accession number
for the Genbank sequence is KJ941050 (Añez et al., 2014). The freeze-
dried preparation contains heat-inactivated virus that has been diluted
in human plasma negative for anti-CHIKV antibodies. This reagent has
been assigned a unitage of 2,500,000 International Units/mL, when
reconstituted as recommended in 0.5 mL of sterile nuclease-free water.
The material has been evaluated in an international collaborative study
involving 25 laboratories performing a wide range of CHIKV NAAT
assays (who-collaborating-study-chikungunya).
A CHIKV RNA reference reagent (RR) was produced in 2015 by the
CBER/FDA (Center for Biologics for Evaluation and Research/US Food
and Drug Administration) (Añez et al., 2015a). It is now available from
the Office of Blood Research and Review, CBER/FDA (Research C
forand. Bl, 2018). The reference reagent consists of cell culture-grown,
heat-inactivated CHIKV diluted in human plasma and frozen. The strain
is also the above-mentioned R91064. In a collaborative study involving
8 laboratories, the RR showed an estimated overall mean of 7.56 log10
detectable units/mL, ranging from 6.2 log10 to 8.6 log10 (Añez et al.,
2015b).
International Standards based on West African and Asian lineages
have not been developed. This is of specific importance, because Asian
lineage of CHIKV has been broadly circulating in Asia, Latin America
and the Caribbean, and there are still episodes of circulation of the West
African lineage of CHIKV in Senegal and most probably in neighboring
countries (Sow et al., 2017; Eastwood et al., 2017).
3.1.6. External quality assessment (EQA)
Four EQAs (Table 2) have been organized to investigate labora-
tories' capability for detection of CHIKV RNA by molecular tools, three
of which were coordinated by the European Network for Diagnostics of
Imported Viral Diseases (ENIVD) (now EVD-LabNet).
Donoso-Mantke et al. (Donoso Mantke and Niedrig, 2007) organized
in 2007 a study involving 24 European laboratories to assess both Ta
bl
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molecular and serological diagnostics for CHIKV. Testing a panel by
molecular tools, a great variability in performances was observed; in
particular, 4 of the 20 laboratories that participated used assays with
low sensitivity and specificity.
In 2007, Panning et al. (2009b) organized an international profi-
ciency study with 31 participants from Europe, Asia, Africa and South
America, who were asked to test the material with any molecular assay
routinely used for detecting CHIKV in human plasma or with a real-time
PCR protocol previously distributed by the study coordinator. In total,
17/31 laboratories lacked adequate sensitivity; those who used the
assay distributed by the consortium showed the highest performances
in term of sensitivity, proving that ad hoc improvement of molecular
diagnostics was possible. False-positive results obtained with nested RT-
PCR, a technique often affected by risk of contamination, confirmed it
as obsolete for routine diagnosis.
In 2014, a third EQA (by Jacobsen et al.) involved 56 international
laboratories from Europe, Asia, Africa, Middle East, Americas,
Caribbean, Oceania (Jacobsen et al., 2016), allowing for worldwide
performance evaluation. Conventional in-house RT-PCR tests had the
highest rate of correct results, although only 5 laboratories used it;
however, low detection rate was observed for the lowest viral load of
the dilution series. In-house real-time RT-PCR systems were the most
commonly used techniques; in particular, systems from Pastorino
(Pastorino et al., 2005) and Panning (Panning et al., 2008) were used
by 9 and 8 out of 42 labs, respectively. As other PCR systems used in the
EQAs (by Lanciotti and Edwards, both used by 3 labs (Lanciotti et al.,
2006; Edwards et al., 2007)), they showed heterogeneous results with
laboratories using the same protocol especially in terms of sensitivity,
suggesting problems associated with laboratory procedures; specificity
and genotyping were more often correctly evaluated. Some commercial
real-time RT-PCRs (used by 13 labs) raised issues for their lack of
sensitivity and specificity (with the closely related ONNV frequently
found positive); however, the identification of these poorly performing
kits was not provided.
The most recent EQA was conducted in 2015 by Soh et al. (2016)
among 24 national-level public health laboratories in the Asia Pacific
region to assess both CHIKV and DENV diagnostics. The majority of
them requested receipt of a CHIKV-positive control and/or real-time or
conventional RT-PCR protocols to develop and validate their capacity
for CHIKV diagnosis. High degrees of sensitivity and specificity were
observed, with 19/20 laboratories (95%) having detected correctly
CHIKV; the only one that detected CHIKV in a serum-only plasma used
a real time RT-PCR protocol.
3.2. Serological diagnosis
3.2.1. Kinetics of the immune response
Virus-specific IgM antibodies appear in the serum within 4–6 days
after the onset of illness (Chusri et al., 2014; Staples et al., 2009). Ac-
cordingly, IgM may be absent at the initial consultation, at the acute
stage of the disease. They generally can be detected up to 3–4 months
after infection (Chusri et al., 2014; Staples et al., 2009; Prince et al.,
2015), but can persist for more than one year, especially for patients
with chronic arthralgia (Malvy et al., 2009; Borgherini et al., 2007). In
case of CHIKV infections with neurological involvement, cerebrospinal
fluid (CSF) can be tested for IgM antibodies (Tournebize et al., 2009;
Mehta et al., 2018). According to case reports, they would appear a
little later than in serum (Taraphdar et al., 2015); moreover, the higher
the IgM titer in the serum, the higher it is in CSF (Gérardin et al., 2016).
IgG antibodies are typically found as early as 6–7 days after illness
onset, a few days after IgM appearance (Chusri et al., 2014; Prince
et al., 2015); like some IgM antibodies, they can directly neutralize
CHIKV multiplication and can persist in immune individuals for many
years (Nitatpattana et al., 2014). In the case of a strong and long-lasting
IgM response, it seems that IgG seroconversion can occur late, with no
IgG detected in some patients 90 days after symptom onset (Bozza et al.,
2019). Among all four IgG isotypes, IgG3 antibodies dominate in the
naturally-acquired IgG response, and they are mostly specific for the E2
protein (Kam et al., 2012a; Verma et al., 2013). Their appearance
during the early convalescent phase has been associated with virus
clearance, long-term clinical protection and better outcome (Kam et al.,
2012b).
Cross-reactivity of CHIKV antibodies has been observed with
members of Semliki Forest serocomplex, especially with viruses having
a close genetic and evolutionary relationship (ONNV, MAYV, ross river
virus-RRV) (Calisher et al., 1986; Karabatsos, 1975; Strauss and Strauss,
1994). It will be discussed more in detail in the paragraph 3.2.8.
3.2.2. Choice of test
After the period of viremia has ended, diagnosis may rely on virus
detection in other fluids or tissues (see above) or on serological assays.
A variety of laboratory diagnostic methods have been developed over
time, including immunofluorescence tests (IFT), haemagglutination-
inhibition assays (HIA), enzyme-linked immunosorbent assays (ELISA)
and neutralization tests (NT).
ELISAs are the most commonly used assays for detection of both IgG
and IgM antibodies. ELISA and IFT, in contrast to HIA and NT, can
make the distinction between IgM and IgG; this is useful because the
detection of IgM, or detection of IgG seroconversion or a four-fold rise
Table 3
Performances of commercial tests for the detection of anti-CHIKV IgM antibodies, according to published evaluations.
Kit Company Method Performance (ref)
Human Anti-CHIKV IgM ELISA Kit Abcam IgM ELISA Lot-to-lot variation: good concordance with CDC results vs low sensitivity (Johnson et al.,
2016)
CHIK IgM ELISA Test CE CTK Biotech IgM ELISA CDC: Low sensitivity (Johnson et al., 2016)
Chikungunya IgM Combo Rapid Test
CE
IgM-rapid test CDC: Low sensitivity (Johnson et al., 2016; Prat et al., 2014; Kosasih et al., 2012; Yap et al.,
2010)
Anti CHIKV IFT EUROIMMUN IFT CDC: High accuracy and reproducibility; Good sensitivity and specificity; Variation in
sensitivity for Ab against different CHIKV strains (Johnson et al., 2016; Yap et al., 2010; Litzba
et al., 2008)
Anti-CHIKV ELISA (IgM) IgM ELISA CDC: High accuracy and reproducibility; Cross-reactivity with anti-ONNV Abs; High
sensitivity; False neg and false pos results (Johnson et al., 2016; Prat et al., 2014; Prince et al.,
2016)
Chikungunya IgM μ-capture ELISA GenWay IgM ELISA CDC: Low sensitivity (Johnson et al., 2016)
Chikungunya IgM μ-capture ELISA IBL International IgM ELISA Cross reactivity with anti-ONNV Abs; False neg and false pos results (Prat et al., 2014)
CHIKjj Detect™IgM ELISA Kit InBios IgM ELISA CDC: High accuracy and reproducibility; High sensitivity (Johnson et al., 2016; Prince et al.,
2016)
SD Chikungunya IgM ELISA SD Standard Diagnostics IgM ELISA CDC: Low sensitivity (Johnson et al., 2016; Blacksell et al., 2011)
SD BIOLINE Chikungunya IgM IgM - rapid
test
CDC: Low sensitivity (Johnson et al., 2016; Prat et al., 2014; Kosasih et al., 2012; Blacksell
et al., 2011)
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in antibody titers in paired specimens (collected during the acute and
convalescent phases of the disease) are generally used as criteria to
make a reliable diagnosis of infection.
3.2.3. Commercial serological tests (IgM)
A search for commercially available tests identified different kits
dedicated to the detection of anti-CHIKV IgM, most of which have been
evaluated in clinical or EQA studies (Johnson et al., 2016; Prat et al.,
2014; Kosasih et al., 2012; Yap et al., 2010; Litzba et al., 2008; Prince
et al., 2016; Blacksell et al., 2011) (Supplementary data-Table 2 and
Table 3). Immunochromatographic rapid tests (CTK and SD Diag-
nostics) are an attractive diagnostic option, but their performances are
characterized by low sensitivity (Johnson et al., 2016; Prat et al., 2014;
Kosasih et al., 2012; Yap et al., 2010; Blacksell et al., 2011). IFT by
EUROIMMUN proved to be highly sensitive and specific (96,9% and
98,3% respectively) (Litzba et al., 2008), although a variation in sen-
sitivity was observed in two independent outbreaks caused by different
strains of CHIKV, possibly due to amino acid differences in the viral E1
and E2 envelope proteins (Yap et al., 2010). Immuno-enzymatic tests
represent the most common commercially available assays, although
performances in terms of sensitivity and specificity are quite diversified.
According to Johnson et al. (2016), who evaluated most of them, IgM
ELISA by EUROIMMUN and InBios have the highest sensibility and
sensitivity (although in a follow-up study EUROIMMUN ELISA was af-
fected by cross-reaction, with detection of anti-ONNV IgM (Prat et al.,
2014)). The Abcam ELISA also gave reliable results, although a con-
siderable batch-to-batch variability was observed; ELISA assays by CTK,
Genway, SD and IBL lacked sensitivity and are not recommended in
their current format.
3.2.4. Commercially available serological tests (IgG)
Some of the commercially available tests for IgG detection have
been evaluated (Supplementary data-Table 3 and Table 4). IFT (im-
munofluorescent test) by EUROIMMUN showed high sensitivity and
specificity (95,4% and 100%, respectively) (Litzba et al., 2008). ELISA
by EUROIMMUN and IBL proved to be specific (95% and 96%), but had
lower sensitivity (88% and 52%); both detected anti-ONNV IgG, and the
EUROIMMUN ELISA also anti-MAYV IgG (Prat et al., 2014).
3.2.5. International standard (IS)
No IS for serological test is currently distributed.
3.2.6. External quality assessment (EQA)
Three EQAs (Table 5) were organized by ENIVD to investigate la-
boratories' capacity for serological detection of CHIKV infections. Do-
noso-Mantke organized in 2007 an EQA analysis that included 24 la-
boratories from 15 European countries (Donoso Mantke and Niedrig,
2007). Of 18 participants that performed serologic assays, 14 tested for
both IgM and IgG and 4 tested only for IgG. Serology testing revealed
greater differences amongst laboratories than molecular testing. Good
performances were proved for 8 out of 14 laboratories testing for both
IgM and IgG, as well as for 3 out of 4 laboratories testing only for IgG;
all the other laboratories lacked in sensitivity. No false-positive reac-
tions from cross-reactivity with antibodies against viruses other than
CHIKV were observed.
In 2007, 30 expert laboratories from 23 countries in Europe, the
Middle East, Asia, Africa, North America and the Caribbean were in-
volved in the second EQA on diagnostic serological proficiency (Niedrig
et al., 2009). Only 6/30 obtained the highest score: for the others, a lack
of sensitivity, especially for IgM, was observed. Most laboratories used
in-house tests; IFT IgM/IgG by EUROIMMUN was the most common
commercial assay. No significant variation in performance was ob-
served when comparing the assay type (immunoenzymatic versus im-
munofluorescence assays) or origin (in-house versus commercial as-
says); a strong variability in diagnostic accuracy was reported among
laboratories using the same commercial assay, probably due to im-
proper handling of samples and/or assays.
The most recent EQA for serological detection of CHIKV was orga-
nized in 2014 (Jacobsen et al., 2016) involving 56 laboratories from 40
countries in Europe, Asia, Africa, the Middle East, the Americas, the
Caribbean and Oceania; 46 and 50 data sets were returned for anti-
CHIKV IgG and IgM, respectively. A lack of sensitivity and, to a lesser
extent, specificity, were more common for IgM detection than for IgG,
with 1/50 and 20/46 laboratories achieving the highest score for IgM
and IgG, respectively. The most widely used type of technology was a
commercial IFT, followed by in-house ELISA, commercial ELISA and in-
house IFT; other techniques such as virus neutralization test (VNT) and
haemagglutination inhibition assays (HI) were rarely used. Commercial
IFT assays were less capable of detecting low IgM titres, but not with
IgG in the same dilution series; in-house ELISAs proved to be more
sensitive than commercial ELISAs, but less sensitive than IFT and VNT.
3.2.7. Cryoglobulinaemia (IgM)
Cryoglobulins are single or mixed immunoglobulins that undergo
reversible precipitation at low temperatures. Cryoglobulinaemia refers
to a condition with cryoglobulins in the serum; it has been described for
several infectious diseases, particularly hepatitis C infection. A high
prevalence of CHIKV-mixed cryoglobulinaemia (MC) (with type II, II-III
or III cryoglobulins) has been described by Oliver et al. (2009) in
CHIKV-infected travellers coming back from the Western Indian Ocean.
According to this study, CHIKV-MC can lead to misdiagnosis of the
disease when ELISAs are performed on samples kept at 4 °C: specific
anti-CHIKV IgM could be trapped in the cryoprecipitate, causing un-
expected seronegativity for patients with clinical suspicion of CHIKV
infection. To circumvent the problem, it is suggested to manage blood
samples as required for any cryoglobulin research: sampling and cen-
trifugation at 37 °C, decantation and serum pre-warming before the
ELISA assays.
3.2.8. Cross-reactivity
Because of phylogenetic relationships among the three viruses,
cross-reactivity, especially between anti-CHIKV and anti-ONNV anti-
bodies, is a major concern when serological tests are performed to make
a reliable diagnosis. Cross-reactivity between anti-ONNV and anti-
CHIKV antibodies has been primarily investigated as MAYV had a dis-
tinct geographic distribution in the past; however, with the appearance
of CHIKV in the Americas (Leparc-Goffart et al., 2014) and MAYV in the
Caribbean (Lednicky et al., 2016), the antigenic relationship between
the two viruses needs to be evaluated more carefully.
CHIKV is closer phylogenetically to ONNV than to MAYV; this
Table 4
Performances of commercial tests for detection of anti-CHIKV IgG, according to published evaluations.
Kit Company Method Performance (ref)
Anti CHIKV IFT EUROIMMUN IFT Good sensitivity and specificity; Variation in sensitivity for Ab against different CHIKV strains (Yap et al., 2010; Litzba
et al., 2008)
Anti-CHIKV ELISA (IgG) IgG ELISA Quite good sensitivity and specificity; Cross-reactivity with anti-ONNV and anti-MAYV Abs; False neg and false pos
results (Prat et al., 2014)
CHIKjjDetect™IgG ELISA Kit InBios IgG ELISA Quite good sensitivity and specificity; Cross-reactivity with anti-ONNV Abs; False neg and false pos results (Prat et al.,
2014)
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explains the substantial cross-reactivity observed for both IgM and IgG
using ELISA and IFT (Eastwood et al., 2017; Calisher et al., 1986; Prat
et al., 2014; Smith et al., 2018). However, there are no documented
studies evaluating the exact incidence of serologic cross-reactivity be-
tween the two viruses. Even in seroneutralization, it is difficult to dif-
ferentiate antibodies against CHIKV and ONNV unless consistent dif-
ferences in reciprocal cross-neutralization occur, which is not typical.
CHIKV and MAYV are more distant phylogenetically, but cross-re-
activity has been observed with both ELISA and IFT (Calisher et al.,
1986; Prat et al., 2014; Hassing et al., 2010); presumably, it is less
extensive than with ONNV, but no accurate estimation of cross-re-
activity incidence between CHIKV and MAYV could be identified in the
literature.
3.2.9. Cross-neutralization and cross-protection
CHIKV-ONNV-MAYV: Cross-neutralization and cross-protection are
important aspects to consider, because of implications for disease
spread, as well as from the perspective of vaccine development. Despite
this, few studies have been performed, suggesting that anti-CHIKV an-
tibodies can neutralize and protect against MAYV and ONNV infections
better than how anti-ONNV and anti-MAYV antibodies can do against
CHIKV infection.
One-way cross-neutralization has been demonstrated for CHIKV-
ONNV, with anti-CHIKV immune serum inhibiting ONNV plaque for-
mation, while antiserum to ONNV is less effective against CHIKV strains
(Chanas et al., 1979). Similar results were observed in studies showing
that serum or monoclonal antibodies (mabs) derived from ONNV-in-
fected animals or humans weakly neutralize CHIKV (Porterfield, 1961;
Blackburn et al., 1995): Blackburn et al. observed that, using an im-
munofluorescent test (IFT), 86% of the mabs against CHIKV reacted
with ONNV, whereas only 53% of the ONNV mabs reacted with CHIKV
strain. A possible explanation could be that, during its evolution, ONNV
has retained most of the CHIKV antigenic sites, whereas some of ONNV
epitopes have undergone greater conformational change, so that mabs
prepared against them neutralize weakly or not at all against CHIKV
(Blackburn et al., 1995).
The ability of anti-CHIKV antibodies to neutralize and protect
against ONNV infection has been recently investigated in vivo: a re-
combinant CHIKV candidate vaccine was demonstrated to elicit a
strong cross-neutralizing antibody response in a mouse model, con-
ferring protection also against ONNV infection (Partidos et al., 2012).
As concerns cross-neutralization between CHIKV and MAYV, a
plaque-neutralization test has showed that MAYV antiserum slightly
neutralizes CHIKV, while no inhibition effect on MAYV has been caused
by CHIKV antiserum (Porterfield, 1961).
Considering overall findings about anti-CHIKV antibodies effect on
MAYV and ONNV, they are diversified and need further assessment.
Porterfield et al. (Porterfield, 1961) showed that CHIKV antiserum
neutralizes efficiently ONNV but not MAYV. These results contrast with
what observed by Fox et al. (2015) using two murine mabs against
epitopes on the B domain of the CHIKV E2 protein: in vitro, they cross-
neutralized MAYV more than ONNV; in a mouse model, they proved to
be able to protect against MAYV infection, and to reduce disease caused
by ONNV.
4. O'nyong-nyong and Mayaro virus
4.1. Molecular diagnosis
4.1.1. Kinetics of viral load and dedicated biological sampling
ONNV: Only few published studies have examined ONNV kinetics;
similarly to CHIKV, ONNV viremia seems to last approximately one
week or less (Kiwanuka et al., 1999).
MAYV: Case reports suggest a very narrow window during which
molecular assays can detect circulating virus. Halsey et al. (2013) ob-
served negative results in two samples collected beyond day 3 ofTa
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symptoms and tested by PCR; similarly, 4 days after the onset of illness
Coimbra et al. could not detect viremia from two MAYV-case blood
samples (Coimbra et al., 2007). However, an extended viremia (10
days) has been observed in an HIV-infected patient, possibly due to his
immunocompromised status (Estofolete et al., 2016).
For both ONNV and MAYV, molecular tests were performed only on
sera collected at the acute stage of infection.
4.1.2. Choice of test
ONNV – MAYV: Suggestions about the choice of test for molecular
diagnosis of infections are the same provided to detect CHIKV infection
and have been discussed in the paragraph 3.1.2.
4.1.3. In house real-time RT-PCR
ONNV – MAYV: Few published studies have described PCR plat-
forms for the detection of ONNV (Smith et al., 2009; Waggoner et al.,
2017a; Liu et al., 2016; Saxton-Shaw et al., 2013); they are listed in
Table 6. As concerns MAYV, an alignment of 20 sequences available in
GenBank, representing the main MAYV lineages, was made to assess
primer sets developed in-house by various laboratories. The results of
this in silico analysis are presented in Table 7; as explained for CHIKV, a
single mutation in the five 3′ terminal positions of a primer can sig-
nificantly compromise its detection capability, so mismatches con-
cerning nucleotides in these positions are highlighted in the table. Most
PCR systems use primers and probe showing one or more mismatches
with MAYV strains.
4.1.4. Commercial molecular tests
ONNV – MAYV: They are not included as target in any commercial
tests.
4.1.5. International standard (IS)
ONNV – MAYV: No international standard for molecular detection
of the two viruses has been developed.
4.1.6. External quality assessment (EQA)
ONNV – MAYV: No EQAs have ever been organized to evaluate
laboratory′ capacity for ONNV and MAYV detection.
4.2. Serological diagnosis
4.2.1. Kinetics of immune response
ONNV: Little is known about the kinetics of the antibody response to
ONNV. IgM antibodies typically peak two weeks after the onset of ill-
ness and persist for about two months (Bessaud et al., 2006; Kiwanuka
et al., 1999), although a few cases have been described with detectable
IgM for 6 months or more (Kiwanuka et al., 1999). Information about
anti-ONNV IgG comes only from two case reports: a traveller returning
from Kenya experienced IgG seroconversion 26 days after disease onset
(Tappe et al., 2014); a report from Chad described a peak in a patient's
IgG titre 68 days after the acute stage of illness (Bessaud et al., 2006).
MAYV: Anti-MAYV antibody kinetics are also poorly documented.
IgM typically appears three days after the onset of illness (Mota et al.,
2015) and lasts for three months or more, but not beyond six months
(Halsey et al., 2013; Mota et al., 2015). In contrast, IgG may persist for
years (Mota et al., 2015). In a case report, the absence of IgG ser-
oconversion was reported in a patient 3 months after onset of illness,
probably because the time between disease onset and the last blood
sampling in this patient was too short to allow Ig class switching
(Receveur et al., 2010).
4.2.2. Choice of test
ONNV-MAYV: Suggestions about the choice of test for serological
diagnosis of infections are the same provided to detect CHIKV infection
and have been discussed in the paragraph 3.2.2.
4.2.3. Commercial serological tests
ONNV: There is no commercial kit for IgM or IgG detection.
MAYV: EUROIMMUN developed an anti-MAYV ELISA (IgM-IgG) but
it has not been evaluated.
4.2.4. International standard (IS)
ONNV-MAYV: No IS for serological tests is currently available.
4.2.5. External quality assessment (EQA)
ONNV-MAYV: No EQA has been organized to evaluate laboratory
capacity for the serologic diagnosis of ONNV or MAYV infection.
4.2.6. Cryoglobulinaemia
ONNV-MAYV: The presence of cryoglobulins in sera from patients
positive for CHIKV infection should have encouraged to assess it for
ONNV and MAYV also. Actually, no study about cryoglobulinaemia in
sera from patients positive for ONNV or MAYV has been performed.
4.2.7. Cross-reactivity, cross-neutralization and cross-protection
These items have been discussed in the paragraph 3.2.8 and 3.2.9.
5. Discussion
The development, validation and evaluation of diagnostic tools are
crucial steps to developing accurate diagnostic methods of alphavirus
infections. A considerable amount of financial resources and efforts are
necessary to implement virus and virus-specific antibody detection.
This justifies why diagnostic tools ideally should be developed before
outbreaks, in order to ensure a rapid response, and it's valid especially
for pathogens showing clear assumptions of large-scale dissemination.
The recent occurrence of extensive CHIKV epidemics has necessi-
tated improved documentation of infection and has impelled labora-
tories and companies to develop specific molecular and serological
assays. However, it has also highlighted the need for improved capacity
for diagnostic surveillance, especially when the co-circulation of closely
related viruses increases the chance of misdiagnosis.
ONNV and MAYV have been discussed in parallel with CHIKV be-
cause their similar clinical presentations, serological cross-reactivity
and geographic areas of co-circulation are significant barriers to specific
diagnosis.
6. Knowledge gaps
6.1. Chikungunya virus
• Kinetics of viral load and dedicated biological sampling: different
kinds of clinical samples have been used for the molecular detection
of the virus. However, for some of them (i.e. urine and breast milk)
the time window for detection of the viral genome remains unclear,
with different authors reporting contradictory results. Comparative
Table 6
Published reports of RT-PCR systems for the detection of ONNV, in decreasing
order of the year of publication.
Year Reference Method Target
2017 Waggoner et al.
(2017a)
Monoplex real time RT-PCR 5′UTR-nsP1
2016 Liu et al. (2016) Real-time PCR-based TaqMan array
card (TAC) (15 viruses)
E1
2013 Saxton-Shaw et al.
(2013)
Monoplex real time RT-PCR E1
2009 Smith et al. (2009) Monoplex real time RT-PCR E1
nsP1
nsP2
Multiplex (OONV-CHIKV) real time
RT-PCR
5′UTR-nsP1
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studies to assess body fluids are missing: they should be performed
to better document kinetics of viral loads and to identify the most
appropriate samples for diagnostic use at the different steps of the
disease.• In-house real-time PCR protocols: several in-house real-time PCR
protocols have been published, with different performances in the
detection of the CHIKV lineages predicted from in silico analyses. An
in vitro analytical evaluation would allow to better assess the ade-
quacy of PCR systems to detect different lineages.• Commercial real-time PCR assays: a large number of commercial
tests are available for molecular diagnosis. The performances of only
one kit have been reported under the form of a scientific article. Kits
datasheets commonly provide insufficient information regarding the
lineage(s) detected and how the performances of the assay were
evaluated. Lack of information about primers and probes used does
not allow assessment of adequacy for covering existing genetic
variability. In the context of External Quality Assessments, some
commercial tests are not clearly identified.• Molecular International Standards: development of IS is essential for
harmonisation of results among different laboratories; however, the
only IS available for molecular diagnosis has been prepared with
one ECSA strain, despite the significant genetic diversity between
CHIKV lineages.• Commercially available serological assays: a large number is avail-
able and several evaluations have been published; however, end-
users would benefit from the guidance of a global and independent
test evaluation.
6.2. O'nyong-nyong and Mayaro virus
• Kinetics of viral load and dedicated biological sampling: few cases
are described in the literature and do not provide a clear picture of
the kinetics of viremia. This could be problematic especially for
MAYV, which may have a shorter window of viremia compared to
CHIKV and ONNV. To the best of our knowledge, no samples other
than sera have been tested, so that kinetics of viral loads in different
body fluids have never been described.• Kinetics of the immune response: it is only documented from a few
case reports; accordingly, it is not clear when antibodies would
appear and how long they would persist in sera.• In-house real-time PCR protocols: a few in-house real-time PCR
protocols have been published for both pathogens. In silico analysis
shows that most primers and probe sets have one or more mis-
matches with some MAYV evolutionary lineages. An in vitro analy-
tical evaluation would allow to better assess the performances of the
PCR systems and their adequacy to detect the different MAYV
lineages.• Commercial molecular and serological tests: none is available for
ONNV; one serological assay (IgM) is available for MAYV, but it has
not been evaluated.• Molecular International Standards: none is available.• External Quality Assessments (EQAs): they have never been orga-
nized to evaluate laboratories' capacity to diagnose ONNV and
MAYV infection.
6.3. All three viruses
• Cryoglobulinaemia: false negative serological results due to cryo-
globulinaemia have been reported for patients infected with CHIKV
(only one study available). The presence and role of cryoglobuli-
naemia have not been investigated for ONNV and MAYV.• Cross reactivity and virus co-circulation: substantial cross-reactivity
between anti-CHIKV and anti-ONNV antibodies, as well as between
anti-CHIKV and anti-MAYV has been reported, but poorly char-
acterized. Differential diagnosis (CHIKV-ONNV and CHIKV-MAYV)
in co-circulation areas is a challenging task. Serological assays
allowing differential identification of the infection by the different
viruses are required.• Cross-neutralization and cross-protection: few studies have been
performed, which limits the ability to assess cross-neutralization
and/or cross-protection.
7. Expert recommendations
7.1. Chikungunya virus
• In-house real-time PCR protocols: the numerous laboratory-devel-
oped protocols would benefit from a shared platform with in silico
analysis of primers and probe sets; it could help to identify the most
appropriate PCR for detection of circulating strains. A similar ser-
vice has been previously proposed by the European Virus Archive
website upon emergence of the CHIKV Asian genotype in the
Caribbean. A host website governed by a non-commercial academic
or public health organization, should be identified to implement this
database and to contain results of laboratory comparative tests.
After having defined mechanism of analysis and collection of results,
this could be proposed as a model for other emerging viral diseases.• Commercially available real-time PCR tests (i): analytical evaluation
and comparative studies of commercial molecular assays should be
performed to assess both sensitivity and specificity. Results of
External Quality Assessments should be made available with a clear
identification of the commercial assays used.• Commercially available real-time PCR tests (ii): to assess the ade-
quacy of commercial tests for genomic diversity of CHIKV, compa-
nies should make publicly available detailed information about
primers and probes sets and/or provide updated performance ana-
lysis of their kits for detection of existing and newly identified
variants.• Serological tests: to better assess laboratory capacity for serological
diagnosis, reference panels should be constituted and tested using
operational tests. This could help to evaluate performances of both
commercial and in-house tests.• Commercially available serological tests: including commercial tests
in EQAs and in comparative studies can help laboratories in their
choice for the most reliable diagnostic assays.
7.2. O'nyong-nyong and Mayaro virus
• In general: both ONNV and MAYV require specific efforts for im-
plementing clinical and epidemiological studies.• Viremia: viremia kinetics, as well as viral loads in different body
fluids, should be better documented.• Immune response: the kinetics of the antiviral IgM and IgG response
should be evaluated during the course of natural infection.• Commercial molecular and serological tests: they should be devel-
oped and evaluated through comparative studies.• International Standards (IS): they should be made available, taking
into account the MAYV genetic heterogeneity.• External Quality Assessments (EQAs): they should be organized to
assess laboratory capacity of detecting ONNV and MAYV with mo-
lecular and serological tools.
7.3. All three viruses
• Kinetics of viral load and dedicated biological sampling: a detailed
analysis of the presence of the viruses in different body fluids over
the course of infection should be performed and lead to a rational
standardization of the process of clinical sampling according to the
clinical presentation and stage of the disease.• In-house real-time PCR protocols: the lack of information about
assay performances could be filled by organizing comparative stu-
dies, with several laboratories testing reference panels by molecular
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methods; the evaluation should include other viruses at risk of cross-
reactivity and different CHIKV and MAYV genotypes, in order to
determine limit of detection (LOD) for each genotype. If necessary,
new protocols for molecular diagnosis should be developed.• Genomic sequence database: experts recommend that a genomic
reference database should be made available similar to those ex-
isting for other viruses (e.g. see the sites of the Virus Variation
Resource (Virus Variation) or the Virus Pathogen Resource (Virus
Pathogen Database and Analysis Resource). This database would
allow to store available sequence data, together with gene and
protein annotations and information about isolation hosts and
sources.• International Standards (IS): it is highly recommended to develop IS
for CHIKV Asian and West-African lineages, as well as for MAYV and
ONNV.• Cryoglobulinaemia: further studies should be implemented to con-
firm and better document the impact of cryoglobulinaemia in un-
expected CHIKV seronegativity, as well as to extend investigations
to ONNV and MAYV infections.• Co-circulation: viral co-circulation requires the development of
molecular and serological multiplex tools to differentiate CHIKV
from ONNV in Africa and from MAYV in Southern and Central
America.• Cross-reactivity: multidirectional studies should be implemented to
better define the exact extent of CHIKV cross-reactivity with ONNV
and MAYV; this would be most probably required obtaining char-
acterized samples for both naturally exposed humans and experi-
mentally infected non-human primates.• Cross-neutralization and cross-protection: cross-neutralization and
cross-protection studies between the three viruses should be im-
plemented, including studies to identify potential ONNV- and
MAYV- specific monoclonal antibodies; as for cross-reactivity,
samples from both naturally exposed humans and experimentally
infected non-human primates should prove useful for this purpose.
In summary, analysis of the currently available literature and con-
sultation of experts indicate that inadequate diagnostics are currently
available for ONNV and MAYV and, to a lesser degree, for CHIKV. Gaps
in diagnostic tools and protocols allowing the identification of the
etiological agent during the course of CHIKV, ONNV and MAYV in-
fections have been identified for both diagnosis during the acute phase
and for the long-term follow-up of patients, as well as for sero-epide-
miological studies.
Diagnosis of the disease at the acute phase relies mostly on mole-
cular detection of the virus genome. Molecular assays have been de-
scribed for CHIKV, ONNV and MAYV but require further evaluation,
standardized protocols and the availability of international standards
representing the genetic diversity of the viruses. Alternatively, diag-
nosis can be provided by the detection of specific IgM, but the exact
extent of cross-reactivity between the three viruses, the sensitivity of
the assays, and the possible interfering role of cryoglobulinaemia re-
quire further investigation. Implementation of reference panels and
EQAs for both molecular and serological assays is necessary.
Regarding sero-epidemiological studies, there is no reported high
throughput assay that enables the different viruses to be distinguished
in areas of potential co-circulation. Even neutralization assays can lead
to ambiguous interpretation. New specific tools and/or improved
standardized protocols are needed to enable large-scale epidemiological
studies of public health relevance to be performed.
Regarding the long-term follow-up of patients infected by CHIKV
(and potentially ONNV and MAYV) there is currently no biological
marker of medical significance associated with disease progression and
prognosis. This obviously requires a complete reassessment and specific
investigation.
Finally, when pathogens emerge or re-emerge, there is little time for
development of diagnostics, which should be designed and validated in
advance to ensure a rapid response. Considering the high risk of future
CHIKV, MAYV and ONNV outbreaks, it is highly recommended that a
major investigation should be initiated to fill existing diagnostic gaps.
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